In Japan the use of guselkumab to treat erythrodermic, plaque and pustular psoriasis is approved, and anakinra is now indicated for Still’s disease in the E.U…
Search results for: juvenile idiopathic arthritis
Clinical Remission Should Be Target of JIA Treatment: Task Force
NEW YORK (Reuters Health)—An international task force says patients with juvenile idiopathic arthritis (JIA) should be treated to a target of clinical remission, among other new recommendations. “The Task Force is convinced that transferring (the recommendations) into clinical practice will significantly improve the outcomes in patients with JIA,” Dr. Angelo Ravelli of the Istituto G….
Have We Reached the Limits of Clinical Classification?
There is an old adage that there are two types of people—lumpers and splitters. For some, people are easily categorized into liberal vs. conservative, Democrat vs. Republican, Donald Trump supporter vs. Hillary Clinton supporter. For others, everyone is a snowflake, and what makes us different is much more important than what makes us the same….
The FDA Approved Several New Rheumatology Drugs in 2017
SAN DIEGO—In a session at the 2017 ACR/ARHP Annual Meeting, Kam Nola, PharmD, MS, professor in the College of Pharmacy and vice chair in the Department of Pharmacy Practice at Lipscomb University in Nashville, Tenn., updated participants on new medications and new indications for rheumatology treatments and safety labeling changes approved by the U.S. Food…
TNF Inhibitors May Not Be Linked to Cancer Risk in Kids
NEW YORK (Reuters Health)—Using tumor necrosis factor (TNF) inhibitors in children is not significantly associated with cancer risk, according to a new study. “TNF inhibitors are remarkably effective for the treatment of many autoimmune conditions, but physicians worry that they cause cancer,” Dr. Timothy Beukelman from the University of Alabama in Birmingham told Reuters Health…
The Why & What of the ACR’s Clinical Practice Guidelines
With the support of its membership, the ACR publishes clinical practice guidelines in multiple disease areas based on the best available clinical and scientific data. These aim to support health professionals treating rheumatology patients to give the best possible care. Like any set of medical guidelines, ACR guidelines are based on evidence of several different…
3 Experts Discuss Bone Health
SAN DIEGO—At the 2017 ACR/ARHP Annual Meeting Nov. 3–8, experts discussed improving bone health in the U.S., gave tips on bone health disorders in pediatrics and reviewed new translational science findings for joint conservation in early osteonecrosis. E. Michael Lewiecki, MD, director of the New Mexico Clinical Research & Osteoporosis Center in Albuquerque, N.M., called…
Experts Discuss the Latest Precision Medicine Research
SAN DIEGO—In just two decades, precision medicine has gone from futuristic concept to realistic toolbox for clinical physicians. At the 2017 ACR Clinical Research Conference on Nov. 3, the Precision Medicine in Rheumatic Diseases: Hopes and Challenges lecture featured rheumatologists and experts on genetics, genomics, pharmacoÂgenetics and big data who spoke about the latest research…
Upadacitinib Receives Breakthrough Designation, Abatacept Use Expands in Australia & More
The FDA has designated upadacitinib a breakthrough therapy to treat adults with moderate to severe atopic dermatitis…
Rheumatology Research Foundation Honors Award Recipients
SAN DIEGO—In November, the Rheumatology Research Foundation honored 155 award and scholarship recipients at the Awards Celebration, an annual luncheon, held in conjunction with the ACR/ARHP Annual Meeting. The event celebrates the accomplishments of rheumatology professionals who have received funding from the Foundation. In congratulating the award recipients, executive director Mary Wheatley, CAE, IOM, emphasized…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 37
- Next Page »